Global mRNA Vaccines & Therapeutics Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global mRNA Vaccines & Therapeutics Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global mRNA Vaccines & Therapeutics market finds that the global mRNA Vaccines & Therapeutics market reached a value of USD 28037.12 million in 2022. It’s expected that the market will achieve USD 2883.86 million by 2028, exhibiting a CAGR of -31.55% during the forecast period.

mRNA Vaccines & Therapeutics Market Opportunities and Drivers

At present, various financing and cooperation activities in the mRNA Vaccines & Therapeutics market are active, and the capital market has good expectations for its development. Since 2015, companies such as CureVac, Arcturus, BioNTech, and Moderna related to the development of mRNA drugs have continued to make breakthroughs in technology, giving capital confidence in this field. Market financing provides funding support for the sustainability of corporate research.

Technically, many innovative companies have linked mRNA drugs to vaccines, nanotechnology, immunotherapy, and gene therapy. The market has strong demand for new drugs, considerable market prospects for technology owners of viable drugs, and the continuous advancement of cuttingedge technologies has provided more opportunities for the entire industry.

Inactivated vaccine is the most traditional vaccine classic technical route. By culturing the new coronavirus in vitro, then inactivating it to eliminate its toxicity, and then returning the inactivated virus to the body. After the inactivated virus enters the body, due to its antigenicity, Can stimulate the immune system to produce antibodies. Inactivated vaccines must be produced in P3 laboratories. If large-scale production is required, the laboratory's biosafety assurance and testing technology must reach world-class levels. Compared with traditional vaccines and DNA vaccines, mRNA vaccines have the advantages of short R&D cycle, relatively low R&D cost, high safety, good water solubility, strong design and rapid preparation, which brings huge imagination to the market.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

The only two commercialized companies are Pfizer-BioNTech and Moderna Therapeutics with a revenue market share of 45.56% n 54.44% in 2020.

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Segmentation Overview:

Among different product types, COVID-19 Vaccines segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Infectious Disease segment occupied the biggest share from 2017 to 2022.

Key Companies in the global mRNA Vaccines & Therapeutics market covered in Chapter 3:

Tiba Biotechnology
eTheRNA
Argos Therapeutics
Moderna Therapeutics
Sangamo Therapeutics
BioNTech
Translate Bio
Ethris
CureVac
In-Cell-Art

In Chapter 4 and Chapter 14.2, on the basis of types, the mRNA Vaccines & Therapeutics market from 2018 to 2029 is primarily split into:

COVID-19 Vaccines
Cancer Vaccines
Other Prophylactic Vaccines
Intratumoral Immuno-Oncology

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the mRNA Vaccines & Therapeutics market from 2018 to 2029 covers:

Infectious Disease
Cancer
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)